Immunology testing for people receiving CAR-T therapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at immune system “fingerprints” in people who are planning to receive CAR-T cells. It may help doctors understand how the immune system responds to CAR-T and improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have CAR-T cells planned as part of approved (marketing-authorized) use
- Be able and willing to sign informed consent
- Have French Social Security coverage
- Be able to attend all required study follow-up visits (travel/social/mental health situation must allow it)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to check how blood cancers respond to immunotherapy. It looks at small blood or bone marrow samples before and during treatment to help doctors choose the best therapy.
This study collects and stores biological samples from people who have been treated with CAR-T cells at the University Hospital of Montpellier. Your samples can help researchers learn more about treatment effects and safety.
This study looks at a biological process called trogocytosis (when immune cells swap pieces of their outer coating) to see if it can help predict how well CAR-T cell therapy works for people with a type of lymphoma called diffuse large B-cell lymphoma.
This study looks at a patient’s genetic (molecular) information while they receive CAR-T cell therapy. The goal is to better understand how different biological factors may affect CAR-T treatment.
This study looks at how patients with blood cancers are managed in real life when they receive CAR-T cell therapy. It helps doctors learn more about how well these treatments work outside of clinical trials.
This study looks at tissue samples from adults who are receiving CAR-T cell therapy for blood-related conditions. It aims to learn more about how CAR-T works and what changes happen in the body, which may help improve future care.
Hear when a new Hematologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.